文献速递肺结节与肺癌慢阻肺

将共存慢性病纳入肺癌筛查患者选择决策:美国胸科学会官方研究声明

Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

美国胸科学会发布官方研究声明,聚焦共存慢性病对肺癌筛查(LCS)结局的影响。多学科国际专家组回顾现有数据,围绕肺癌风险与竞争性死亡风险的权衡、慢阻肺患者的获益与风险、风险沟通及筛查检出肺癌的治疗等议题,识别知识空白并提出研究框架,以指导未来患者选择与筛查实施。

要点

  • 共存慢性病与竞争性死亡风险可改变肺癌筛查的获益-危害平衡。
  • 需综合评估基线肺癌风险、治疗相关危害与竞争性死亡风险。
  • 声明提出研究框架,优先解决慢性病如何纳入筛查决策与沟通的问题。

核心结论

  • 亟需进一步研究以指导对因共存慢性病可能无法从肺癌筛查中获益患者的临床决策。
  • 该声明建立了研究框架,以解决如何将共存疾病风险纳入并沟通于肺癌筛查患者选择与决策的核心问题。

研究设计与样本

  • 美国胸科学会官方研究声明,由国际多学科临床医生与研究者组成专家组。
  • 专家组回顾共存疾病对肺癌筛查结局影响的现有数据,并识别知识与研究空白、优先排序议题、提出未来研究方法。

主要发现

  • 声明识别了关于共存疾病与竞争性死亡原因如何影响肺癌筛查结局的知识空白。
  • 专家组提出了一系列问题,以引导未来研究更好地 informing 患者选择、教育与肺癌筛查实施。

关键数值与推荐

  • 关注肺癌风险与竞争性死亡风险的并置权衡。
  • 考虑慢阻肺患者的获益与风险。
  • 关注风险沟通与筛查检出肺癌的治疗。

临床怎么用

  • 临床决策时应综合评估患者的肺癌基线风险、治疗相关危害与竞争性死亡风险。
  • 对共存慢性病患者,需个体化权衡肺癌筛查的获益与危害,避免对可能无法获益者过度筛查。

局限性

  • 声明基于现有数据回顾,共存慢性病对肺癌筛查结局的影响尚未充分明确。
  • 声明识别了知识空白,未提供新的定量证据或推荐阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer screening (LCS) has the potential to reduce the risk of lung cancer death in healthy individuals, but the impact of coexisting chronic illnesses on LCS outcomes has not been well defined. Consideration of the complex relationship between baseline risk of lung cancer, treatment-related harms, and risk of death from competing causes is crucial in determining the balance of benefits and harms of LCS. OBJECTIVES: To summarize evidence, identify knowledge and research gaps, prioritize topics, and propose methods for future research on how best to incorporate comorbidities in making decisions regarding LCS. METHODS: A multidisciplinary group of international clinicians and researchers reviewed available data on the effects of comorbidities on LCS outcomes, focusing on the juxtaposition of lung cancer risk and competing risks of death, consideration of benefits and risks in patients with chronic obstructive pulmonary disease, communication of risk, and treatment of screen-detected lung cancer. RESULTS: This statement identifies gaps in knowledge regarding how comorbidities and competing causes of death impact outcomes in LCS, and we have developed questions to help guide future research efforts to better inform patient selection, education, and implementation of LCS. CONCLUSIONS: There is an urgent need for further research that can help guide clinical decision-making with patients who may not benefit from LCS owing to coexisting chronic illness. This statement establishes a research framework to address essential questions regarding how to incorporate and communicate risks of comorbidities into patient selection and decisions regarding LCS.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Rivera MP, Tanner NT, Silvestri GA, et al. Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2018. PMID: 30004250. doi:10.1164/rccm.201805-0986ST

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。